Company expects to deliver 50,000 tests per day of the rapid, instrument-based, isothermal system designed for qualitative detection of infectious diseases.
The study used four adult Chinese rhesus macaques and found that those monkeys that had been re-exposed to SARS-CoV-2, like the unexposed control monkey, showed no recurrence of COVID-19.
Gardnerella bacteria were the dominant biomarker for the progression of HR-HPV and its effect is mediated by increased cervicovaginal bacterial diversity directly preceding the progression of a persistent infection to precancer.
A notable addition to the effort is a team from the University of Birmingham, led by Nick Loman, Ph.D., professor of Microbial Genomics and Bioinformatics in the Institute of Microbiology and Infection, whose lab is known for fusing cutting-edge sequencing with microbial genomics.
The study could signal a potential treatment breakthrough for patients with this form of breast cancer, which disproportionately affects and tends to develop more aggressively in black women.
Scripps researchers compare available genome sequence data for known coronavirus strains to determine that that SARS-CoV-2 originated through natural processes and note that their results “clearly show that SARS-CoV-2 is not a laboratory construct or a purposefully manipulated virus.”
GenapSys’ sequencing system is about the size of an iPad, costs under $10,000, and is based on a proprietary direct electronic sequencing chip, which is intended to eliminate the need for cumbersome equipment.
Emergency Use Authorization (EUA) would enable Biodesix and Bio-Rad to begin testing in the U.S. using the Droplet Digital PCR system.
The companies will partner on a proof-of-concept project focused on detection of SARS-CoV-2 coronavirus as the first initiative of a broader collaboration focused on developing molecular diagnostic tests for infectious diseases and oncology.
Up-and-Coming Diagnostic Test Developers Emerge as Consolidation Thins the Field.